Drugs / MRZ-99030
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01714960 | Oct 2012 → Dec 2013 | — | Merz Pharmaceuticals GmbH | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-11-08 | Galimedix Therapeutics Inc | Results New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects galimedix.com ↗
Even after a thousand-fold dilution below predicted therapeutic levels, it prevented the formation of these toxic oligomers and even reversed their toxic effects by rapidly capturing the misfolded proteins into harmless “blobs” that continued their work even after the drug dropped below minimal levels. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2018-11-08 | Galimedix Therapeutics Inc | New In Vitro Study Demonstrates Galimedix Therapeutics’ Investigational Compound MRZ-99030 Neutralizes the Reproduction of Misfolded Amyloid-Beta, Thereby Potentially Reducing Synaptotoxic Effects galimedix.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRZ-99030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01714960 ↗ |
| Route | Topical | “repeat dose topical administration” NCT01714960 ↗ |